Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.48 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17375372 | 0.90 | BTK (0.53) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL16078924 | 0.82 | DPP8 (0.41) | BTKTNK2 | |
| SCHEMBL27586498 | 0.79 | NUDT14 (0.58) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL17264218 | 0.75 | BTK (0.71) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL28747962 | 0.74 | NUDT14 (0.61) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19176242 | 0.74 | NUDT14 (0.58) | BTKEGFRLCKSRCABL1 | |
| SCHEMBL17377409 | 0.73 | CTSS (0.43) | BTKEGFRSRCTNK2 | |
| SCHEMBL25069027 | 0.72 | SRC (0.76) | EGFRLCKSRCABL1NUDT14 | |
| SCHEMBL1612513 | 0.72 | EGFR (0.50) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL1682621 | 0.72 | SRC (0.50) | BTKEGFRLCKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156847-B2 | Processes and intermediates for preparing a medicament | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-13 | — | — | US | disclosed |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139970-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | BTK 1/4885EGFR 881/4885LCK 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.